Pancreatic Cancer mRNA Vaccine Shows Lasting Results Six Years On

Pancreatic cancer is among the most lethal of all cancers, with fewer than 13% of patients surviving five years, so any durable progress draws attention. On 19 April 2026, at the American Association for Cancer Research annual meeting, researchers from Memorial Sloan Kettering Cancer Center shared follow-up data showing that a personalized mRNA vaccine produced immune responses that have lasted up to six years in some patients.

The vaccine, autogene cevumeran, is custom-made for each patient. After surgery to remove the tumor, scientists analyze its unique mutations and design a vaccine to train the immune system to recognize and attack any cancer cells that remain. The early-phase trial, led by Dr. Vinod Balachandran, enrolled 16 patients with early-stage pancreatic cancer; eight of them mounted an immune response to the vaccine.

“On 19 April 2026, at the American Association for Cancer Research annual meeting, researchers from Memorial Sloan Kettering Cancer Center shared follow-up data showing that a personalized mRNA vaccine produced immune responses that have lasted up to six years in some patients.”

The long-term outcomes are striking. Among the eight patients who responded, seven — roughly 88% — were still alive four to six years after surgery. By contrast, among the eight who did not respond, only two were alive, with a median survival of about 3.4 years. "These early results show this new immunotherapy approach has the potential to make a difference for one of the deadliest cancers," researchers said, pointing to the unusually durable immune memory the vaccine appears to generate.

The caveats are real and important. This was a small, early-phase study designed mainly to test safety and feasibility, not a large randomized trial, so the survival figures cannot yet prove the vaccine caused the benefit. A larger, randomized study is under way to test the approach more rigorously, and results will take years. Even so, watching personalized mRNA vaccines — the same broad technology behind COVID-19 shots — generate years-long immune responses against a cancer with so few good options is a genuinely hopeful sign of where treatment may be heading.